Stevenson Ryan, Libutti Steven K, Saif Muhammad Wasif
Tufts University School of Medicine, Boston, MA, USA.
JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470.
Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.
神经内分泌肿瘤（NET）是一组源自具有神经内分泌分化的上皮细胞的多种肿瘤。胃肠胰神经内分泌肿瘤是NET的一个子集，起源于胃肠道。临床症状和表现因肿瘤的位置和产生的激素而异。传统上，晚期和转移性胃肠胰NET的治疗一直很困难，全身治疗选择很少。2011年，两种新的靶向疗法依维莫司和舒尼替尼被批准用于治疗胰腺NET，这导致人们对在胃肠胰NET中具有活性的新型药物的兴趣增加。在2013年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上，两篇摘要展示了有关新型疗法的新数据。伦巴德 - 博阿斯等人（摘要#224）展示了来自RADIANT - 3试验的新数据，沈等人（摘要#322）研究了奥曲肽在老年类癌综合征患者中的应用。
